2024年制药研发年度回顾信息图

Pharma R&DAnnual Review 2024InfographicInsights from our annual reviewof trends in pharmaceutical R&D Even as overall pipeline numbers increase, the number of drugsadvancing to Phase III clinical trials appears to be slowing down.The number of candidates in Phase III rose only 1.5% from 2023to 2024. Things were sunnier in terms of drugs emerging from thepipeline, with registered drugs up 28.9% and launches rising 9.9%. Top 10 pharma companies by size of pipelineAcquisitions helped boost the pipeline rankings of several of the top10 companies in 2024, including Pfizer, Eli Lilly, and AstraZeneca.Novartis slipped from second to sixth due to a pipeline trim, andJiangsu Hengrui Pharmaceuticals became the first China-basedcompany ever to enter the top 10 thanks to its 38.7% pipeline growth.